Treatment Update of Autoimmune Blistering Diseases

Khalaf Kridin; Christine Ahn; William C. Huang; Ahmed Ansari; Naveed Sami

doi:10.1016/j.det.2018.12.003

Treatment Update of Autoimmune Blistering Diseases

Khalaf Kridin, Christine Ahn, William C. Huang, Ahmed Ansari, Naveed Sami

Research output: Contribution to journal › Review article › peer-review

Abstract

The treatment of refractory autoimmune blistering diseases (AIBDs) has always been a challenge. Because randomized controlled trials are lacking, treatment has been based on analysis of anecdotal data. The last 2 decades has seen the use of rituximab become a conventional treatment in the therapeutic armamentarium of AIBDs, leading to its Food and Drug Administration indication for pemphigus vulgaris in 2018. We review the current updated data on the use of rituximab including dosing, protocols, and its role in the algorithm of AIBDs. In addition, we discuss several promising novel emerging therapeutic agents for AIBDs.

Original language	English
Pages (from-to)	215-228
Number of pages	14
Journal	Dermatologic Clinics
Volume	37
Issue number	2
DOIs	https://doi.org/10.1016/j.det.2018.12.003
State	Published - Apr 2019
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2018 Elsevier Inc.

Keywords

Autoimmune blistering diseases
Emerging
Rituximab
Treatment

ASJC Scopus subject areas

Dermatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.det.2018.12.003

Cite this

@article{0fcd187373404423bfc5e11d52a799ed,

title = "Treatment Update of Autoimmune Blistering Diseases",

abstract = "The treatment of refractory autoimmune blistering diseases (AIBDs) has always been a challenge. Because randomized controlled trials are lacking, treatment has been based on analysis of anecdotal data. The last 2 decades has seen the use of rituximab become a conventional treatment in the therapeutic armamentarium of AIBDs, leading to its Food and Drug Administration indication for pemphigus vulgaris in 2018. We review the current updated data on the use of rituximab including dosing, protocols, and its role in the algorithm of AIBDs. In addition, we discuss several promising novel emerging therapeutic agents for AIBDs.",

keywords = "Autoimmune blistering diseases, Emerging, Rituximab, Treatment",

author = "Khalaf Kridin and Christine Ahn and Huang, {William C.} and Ahmed Ansari and Naveed Sami",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = apr,

doi = "10.1016/j.det.2018.12.003",

language = "English",

volume = "37",

pages = "215--228",

journal = "Dermatologic Clinics",

issn = "0733-8635",

publisher = "W.B. Saunders",

number = "2",

}

TY - JOUR

T1 - Treatment Update of Autoimmune Blistering Diseases

AU - Kridin, Khalaf

AU - Ahn, Christine

AU - Huang, William C.

AU - Ansari, Ahmed

AU - Sami, Naveed

PY - 2019/4

Y1 - 2019/4

N2 - The treatment of refractory autoimmune blistering diseases (AIBDs) has always been a challenge. Because randomized controlled trials are lacking, treatment has been based on analysis of anecdotal data. The last 2 decades has seen the use of rituximab become a conventional treatment in the therapeutic armamentarium of AIBDs, leading to its Food and Drug Administration indication for pemphigus vulgaris in 2018. We review the current updated data on the use of rituximab including dosing, protocols, and its role in the algorithm of AIBDs. In addition, we discuss several promising novel emerging therapeutic agents for AIBDs.

AB - The treatment of refractory autoimmune blistering diseases (AIBDs) has always been a challenge. Because randomized controlled trials are lacking, treatment has been based on analysis of anecdotal data. The last 2 decades has seen the use of rituximab become a conventional treatment in the therapeutic armamentarium of AIBDs, leading to its Food and Drug Administration indication for pemphigus vulgaris in 2018. We review the current updated data on the use of rituximab including dosing, protocols, and its role in the algorithm of AIBDs. In addition, we discuss several promising novel emerging therapeutic agents for AIBDs.

KW - Autoimmune blistering diseases

KW - Emerging

KW - Rituximab

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85061537496&partnerID=8YFLogxK

U2 - 10.1016/j.det.2018.12.003

DO - 10.1016/j.det.2018.12.003

M3 - Review article

C2 - 30850044

AN - SCOPUS:85061537496

SN - 0733-8635

VL - 37

SP - 215

EP - 228

JO - Dermatologic Clinics

JF - Dermatologic Clinics

IS - 2

ER -

Treatment Update of Autoimmune Blistering Diseases

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this